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ABSTRACT 
Purpose: To investigate the performances of two commercial treatment planning systems (TPS) 
for Volumetric Modulated Arc Therapy (VMAT) optimization regarding prostate cancer. The 
TPS were compared in terms of dose distributions, treatment delivery parameters and quality 
control results.  
Materials and Methods: For ten patients, two VMAT plans were generated: one with Monaco 
TPS (Elekta) and one with Pinnacle TPS (Philips Medical Systems). The total prescribed dose 
was 78 Gy delivered in one 360° arc with a Synergy® linear accelerator equipped with a MLCi2®.  
Results: VMAT with Monaco provided better homogeneity and conformity indexes but lower 
mean dose to PTVs than Pinnacle. For the bladder wall (p=0.019), the femoral heads (p=0.017), 
and healthy tissues (p=0.005), significantly lower mean doses were found using Monaco. For the 
rectal wall, VMAT with Pinnacle provided a significantly (p=0.047) lower mean dose, and lower 
dose into 50% of the volume (p=0.047) compared to Monaco. Despite a greater number of 
monitor units (factor 1.5) for Monaco TPS, the total treatment time was equivalent to that of 
Pinnacle. The treatment delivery parameter analysis showed larger mean MLC area for Pinnacle 
and lower mean dose rate compared to Monaco. The quality control results gave a high passing 
rate (> 97.4%) for the gamma index for both TPS but Monaco provided slightly better results.  
Conclusion: For prostate cancer patients, VMAT treatment plans obtained with Monaco and 
Pinnacle offered clinically acceptable dose distributions. Further investigations are in progress to 
confirm the performances of the two TPS for irradiating more complex volumes.  
 
Keywords: VMAT, Pinnacle, Monaco, Prostate Cancer
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INTRODUCTION 
Volumetric modulated arc therapy (VMAT) is a new radiotherapy technique which allows to 
achieve treatment plans of similar or improved quality compared to fixed-field intensity-
modulated radiation therapy (IMRT) while reducing the treatment time per fraction [1]. In 
practice, to obtain highly modulated dose distributions delivered efficiently, a treatment planning 
system (TPS) with a powerful optimization and segmentation algorithm is required. 
While a lot of users are in the process of replacing fixed-field IMRT by VMAT, or directly 
implementing VMAT in their radiotherapy department, there is a lack of information concerning 
the relative performances of the mainly used TPS for VMAT planning. To our knowledge, only 
three studies deal with this topic [2-4]. In Rao et al, ERGO++ (Elekta, Crawley, UK) was 
compared to Pinnacle (Philips Medical Systems, Madison, WI) direct machine parameter 
optimization (DMPO) combined with a home-made arc-sequencer and Pinnacle SmartArc inverse 
planning module [2]. In Masi et al, the performances of Monaco (CMS-Elekta, Crawley, UK) 
were compared to ERGO++ and Oncentra (Nucletron-Elekta) [3]. Finally, in Wiezorek et al, 
VMAT plans obtained with Monaco and Eclipse (Varian Medical System, Palo Alto, CA) were 
evaluated [4]. In these studies, the comparisons were made by fixing common planning 
objectives on PTVs and OARs and comparing the dosimetric results and treatment delivery 
efficiency (number of monitor units and treatment time). 
 
The aim of the present study was to investigate the performances of two TPS that have not been 
compared yet in VMAT mode, both using different approaches for VMAT plan optimization: 
Monaco based on a two-stage constrained optimization [5] and Pinnacle SmartArc [6]. This work 
was performed by two institutions. The aim was to compare VMAT plans performed by Monaco 
and Pinnacle regarding to dosimetric performances and treatment delivery specificities. We 
therefore fully put in evidence the differences observed in terms of dose distributions, delivery 
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efficiency, treatment delivery parameters (mean dose rate, mean segment area) and quality 
control results on 10 prostate cancer cases.  
 
MATERIALS AND METHODS  
Patients 
Ten prostate adenocarcinoma patients referred to our institutions for a radical external beam 
irradiation to the prostate and seminal vesicles (SV) were considered for this dosimetric 
comparative analysis. 
 
Anatomic data acquisition, volumes definition and dose 
Organs at risk [rectal wall (5 mm thickness), bladder wall (7 mm thickness), femoral heads (FH)] 
and target volumes (prostate, SV) were delineated on dedicated 2 mm-thick CT slices. 
The first clinical target volume (CTV1) comprised the prostate and SV. The CTV2 was limited to 
the prostate only. Planning target volumes (PTVs) were automatically generated adding a 3D 
1 cm uniform margin around the CTVs, except in the posterior direction, where a 0.5 cm margin 
was added to protect the rectum. 
The total prescription dose was 46 Gy to the PTV1 and an additional 32 Gy to the PTV2 using a 
standard fractionation (2 Gy per fraction, 5 days a week) for a total dose of 78 Gy using a 
sequential technique. 
A dose objectives set was fixed for PTVs and OARs : for  PTV1 : 95% of the PTV covered by 
97% of the prescribed dose, and less than 5 % of the PTV receiving more than 107% of the 
prescribed dose; PTV2: 95% of the PTV covered by 95% of the prescribed dose; Rectum: 
maximum dose (into 1.8 cc) < 76 Gy, V72  25% , V60  50% ; Bladder V70  25%, V60  
50%; Femoral heads: V50  5%. 
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Treatment planning 
For each patient, two VMAT plans were generated: one with Monaco 3.0 (CMS-Elekta Ltd, 
Crawley, UK) and one with Pinnacle 9.0 (Philips Medical Systems, Madison, WI).  
The irradiation was delivered, using 6-MV photons with an Elekta Synergy® machine equipped 
with a Cone-Beam Computed Tomography (CBCT) device (XVI®) and with a multi-leaf 
collimator (MLCi2®) consisting of 40 paired leaves, each measuring 1 cm in width at the 
isocenter. The possible dose rate values were 25 MUs/min, 50 MUs/min, 100 MUs/min, 200 
MUs/min and 400 MUs/min. For each treatment plan a single 360° arc was used. 
MONACO PLANNING 
For Monaco planning, the optimization constraints were established on the basis of biological 
cost functions (i.e. Serial or parallel complication model for OARs and Poisson cell kill function 
for the PTVs). The prescription template applied to all patients is given in Table 1. The 
optimisation was first performed in a constrained mode, meaning that all constraints to the OARs 
are treated as hard constraints and all optimization criteria must be met. Conversely, the 
constraints to the targets are considered as objectives. The pareto mode which gives priority to 
PTV coverage was used secondarily to achieve the PTV coverage detailed above. 
Sequencing parameters used for PTV1 and PTV2 irradiation were: 124 control points (CP) to 
achieve in practice 120 CP; target dose rate 300 MUs/min; minimum segment width 0.5 cm; 
fluence smoothing: low.  
For final Monte Carlo dose calculations, a calculation grid of 3 mm and a 3 % variance were 
used. With these parameters, the time needed for final dose calculation was about 10 min on an 
Intel Xeon CPU 3 GHz and 12 GB RAM platform. The time for optimisation stage and adjusting 
the prescription parameters was about 20 min.  
PINNACLE PLANNING 
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For Pinnacle planning, inverse optimization was performed using the SmartArc algorithm (6). 
The optimization objectives were defined with physical dose points. The template is shown in 
Table 1. The arc sampling parameter was fixed at 3 degrees to obtain 120 CP for the full arc. The 
delivery time parameter was fixed at 180 s firstly; then was eventually increased to 240 s to allow 
more dose modulation for the most complex cases. Final dose was computed with a collapsed 
cone algorithm using a dose grid resolution of 3 mm. With these parameters, the time needed for 
optimization and final dose calculation was about 13 min on an Intel quadruple-Core (Xeon) 2.8 
GHz and 16 GB RAM platform. Time for parameters adjustment was 10 min.   
 
Preliminary work 
Although this study was performed by two institutions, an important number of constraints were 
set to limit the influence of the planners and planning philosophy of the two hospitals. First, a 
preliminary comparison study was performed on a water-equivalent cylindrical phantom with a 
C-Shape target surrounding a central avoidance structure (data not shown) as described by the 
AAPM task group 119 [7]. This preliminary work allowed to harmonize both planning methods 
and to verify that for a simple geometry both institutions were able to produce plans of similar 
quality regarding dose distribution and delivery efficiency.  
 
Treatment plans comparisons 
DOSE DISTRIBUTION 
In order to limit the uncertainties on DVHs calculations between both TPS, the results were 
evaluated in the ARTiView 1.12 software (Aquilab, Lille, France) by comparing DVHs for 
targets and OARs (mean dose and doses at selected points of the DHVs). Patient-averaged DVHs 
were compared. In addition, several quality indexes for PTV1 and total plans were assessed: 
homogeneity index (HI) was calculated as (D5% - D95%)/Dmean within the PTV; D5% and D95% 
being the dose received by 5 and 95 % of the PTV [8] ; conformity index (CI) was calculated as 
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the ratio between the volume of the reference isodose (V95%) and the PTV volume (VPTV) 
[V95%/VPTV] [9]; healthy tissue coverage index (HCO) evaluates the percentage of reference 
isodose which is outside the PTV volume. HCO was calculated as [100*(1-(VPTV, 95%/V95%))]; V 
PTV, 95% was the volume of PTV covered by the reference isodose.  
Statistical analysis used two-sided Wilcoxon-signed rank test, a nonparametric test, calculated 
with PASW Version 18.0.0 (SPSS Inc., Chicago, IL). A value of p<0.05 was considered 
statistically significant. 
To underscore the spatial localization differences between the two TPS, a patient-averaged dose 
distribution was performed. To obtain the averaged dose distribution, the anatomy of all the 
patients was registered to a typical patient anatomy. After an initialization done by an affine 
registration, we used an organ-driven non-rigid registration method using the demons algorithm 
between the CTs and between each considered organ (prostate, bladder, rectum). The final 
deformation field was computed by merging the different deformation fields by weighting them 
according to the distance between voxels and organs [10-12]. The transformation was then 
applied to the dose distribution.  
ROBUSTNESS 
In case of daily CBCT, we assume to have a geometric accuracy better than 2 mm as mentioned 
in the AAPM recommendations [13]. To investigate the robustness of Monaco and Pinnacle dose 
distributions, an isocenter shift of 2 mm was applied on one representative prostate case in 
unfavorable directions for the main OARs (i.e. in anterior and posterior direction).  The impact on 
dose distribution was judged with the quality indexes described previously for PTV2, rectum wall 
and bladder wall. 
DELIVERY EFFICIENCY  
The delivery time, MU per fraction, mean dose rate and time-average MLC aperture area were 
used to evaluate the VMAT delivery efficiency. 
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Quality assurance 
In order to evaluate the dose algorithm accuracy of Monaco and Pinnacle, the consistency 
between calculated and delivered dose was verified for one typical plan with EBT3 radiochromic 
films (Ashland, Covington, USA) in a pelvis anthropomorphic phantom (CIRS, Norfolk, USA).  
A dosimetric validation was then performed for all plans with the Octavius phantom (PTW, 
Freiburg, Germany). The dose delivery was measured using the PTW 2D-array Seven29 (PTW) 
ionization chamber matrix. The dose was measured in coronal and sagittal planes.  
Comparisons were performed with Verisoft software (PTW). The 3D gamma method was used to 
compare the measured dose distributions with the calculated 3D dose distribution. The dose 
criterion was 3% of  the local dose and the distance criterion was 3 mm. The evaluated areas were 
areas with doses higher than 30% of the maximum dose.  
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RESULTS 
Dose distribution  
The patient-averaged differences in the dose distributions for the two TPS are shown in Figure 1. 
Large differences are observed. First, Monaco favoured the dose delivery on gantry angles that 
allowed crossing a minimum volume of healthy tissue to reach the PTV. Therefore, the volume of 
healthy tissue receiving higher doses was more important with Pinnacle than with Monaco. 
Furthermore, we observed that Pinnacle solutions result in more dose delivered on the left-right 
direction (i.e. around the FH), whereas Monaco solutions result in more doses delivered on the 
antero-posterior direction (i.e. around the bladder and the rectum). 
 
The averaged dose-volume histograms (DVHs) of total plans are shown in Figure 2. The 
continuous lines represent the mean values and are surrounded by two dashed curves representing 
the 2.5th percentiles of the data for the lower dashed curves and the 97.5th percentiles for the 
upper dashed curves. DVHs data for PTVs and OARs and conformal indexes are reported in 
Table 2 as averages for the investigated patients. Figure 2 shows that Pinnacle plans resulted in 
more dose into the PTVs than Monaco but with a more important scattering. While the mean dose 
to PTV1 was significantly different between both modalities (p=0.008), the difference was not 
statistically significant on PTV2 (p=0.241) (Table 2). 
Furthermore, Monaco plans had higher conformality with significantly better CI and HCO at the 
expense of significantly lower dose homogeneity into the PTV than Pinnacle. Regarding the dose 
distribution to the OARs, Monaco provided a significantly lower mean dose to the bladder wall 
(p=0.019), to the FH (p=0.017) and to the healthy tissue (p=0.005) while Pinnacle provided a 
significantly lower mean dose (p=0.047) and a lower D50% value (p=0.047) for the rectal wall 
(Table 2 and Figure 2).  
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Robustness 
Details of dose with and without isocentre shift for the main organs are shown Table 3. For the 
rectal wall, the 2-mm posterior shift resulted in an increase of the Dmax of 1.3 Gy for both TPS, 
and an increase of the Dmean of 1.9 and 1.7 Gy for Monaco and Pinnacle plans, respectively. The 
D95% to PTV2 was the same for Monaco plans and resulted in an increase of 0.3 Gy for Pinnacle 
plans. For the bladder wall, the 2-mm anterior shift resulted in an increase of the Dmax of 0.3 Gy 
and 0.2 Gy and an increase of the Dmean of 0.8 and 0.7 Gy, for Monaco and Pinnacle plans, 
respectively. The D95% to PTV2 was decreased of 0.7 and 1.3 Gy for Monaco and Pinnacle plans, 
respectively. 
 
Treatment delivery evaluation  
Details of efficiency parameters are shown in Table 4; Figure 3 shows the variations of MLC 
aperture area and dose rate as a function of gantry angle during typical VMAT delivery. Monaco 
plans needed one and a half more MUs than Pinnacle plans. Nevertheless we noticed similar 
delivery times because the time-averaged dose rates were higher with Monaco (230 MUs/min) 
than with Pinnacle (160 MUs/min).  
The better efficiency of Pinnacle plans was due to a larger MLC aperture area (Fig. 3, Table 4). 
On average, total MUs to MLC aperture area ratio was 265 MUs/cm² for Monaco plans and 
 110 MUs/cm² for Pinnacle plans. 
The variation of the area according to the gantry angle (Fig. 3) shows that the segmentation is 
based on an alternative Sliding Window pattern for Monaco VMAT (i.e. all the leaves moves first 
on one way and then on the other way alternatively for the full arc) .  
 
Quality assurance 
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The analysis of the films placed inside an anthropomorphic phantom showed that 99.1% and 
98.4% of the points passed the 3%/3 mm criterion with mean gamma values of 0.34 and 0.31 for 
Monaco and Pinnacle respectively. Central area encompassing the PTV showed high consistency 
between calculated and delivered dose for Pinnacle and Monaco; the mean gamma values were 
0.29 for both TPS.  
The results obtained with the 2D matrix ionisation chamber showed a high passing rate (> 97.4%) 
for the gamma index for both TPS (Table 4). Nevertheless, Monaco provided better dosimetric 
agreement than Pinnacle. To explain the QA results differences, we investigated the dose-
gradient values [14] in the two measurement plans of the Octavius phantom (Table 4). For 
coronal planes, mean dose-gradients were similar for both TPS but maximum dose-gradient was 
higher with Pinnacle. For sagittal planes, all reported dose-gradient values were higher with 
Pinnacle.  
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DISCUSSION 
The aim of the present study was to investigate the performances of Monaco and Pinnacle TPS 
for VMAT plan optimization. To our knowledge, this is the first study yielding a global 
comparison of two TPS for VMAT planning, from the prescription phase and dose distribution 
evaluation to the delivery efficiency. We also included beam geometry, treatment delivery 
parameters and quality control results.  
 
For prostate cancer, VMAT solutions proposed by both TPS offered good PTV coverage and 
OARs sparing, with similar delivery time. Note that the lowest doses to the OARs were achieved 
with Monaco, except for the rectal wall. Regarding dose distribution and delivery parameters 
large differences were observed. First on dose distribution, we noticed that Monaco favoured the 
dose delivery from gantry angles that allowed crossing a minimum volume of healthy tissue to 
reach the PTV. As a consequence, much lower doses were delivered to the FH in comparison 
with Pinnacle, despite the fact that contrarily to Pinnacle, no constraint was assigned to the FH on 
Monaco prescription. Likewise, healthy tissue contained in the CT area received less dose with 
Monaco than with Pinnacle. However, this result must be taken with care since the uncertainties 
in TPS dose calculation are generally larger in the lower dose regions. Indeed, the uncertainty in 
Monte Carlo calculation is influenced by the variance reduction techniques and inversely 
proportional to the square root of the number of histories used for dose calculation. The 
uncertainty of the entire plan is always less than the variance value for dose calculation since that 
value is per segment (i.e. 3 % in our case, for Monaco TPS). Therefore the noise which can be 
observed is substantially reduced in high dose area where a more important number of segments 
contribute to the dose (superposition effect) [15] .   
Furthermore, it is well known that the main part of out-of-field doses are due to the linac-head 
scatter and leakage radiation, proportional to MUs [16;17]. In this case Monaco could provide a 
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higher out-of-field dose. Hence, both TPS provide different irradiation patterns regarding low 
doses without superiority of one TPS was clearly demonstrated. 
 
Finally, higher doses were delivered in the antero-posterior direction, above the bladder or below 
the rectum with Monaco compared to Pinnacle. Therefore, with Monaco TPS, an anatomical 
deformation of the rectum or bladder will probably have more consequences on the delivered 
dose to these organs. In particular, it has been shown that the relative volume of the rectum can 
vary by more than 150% from one day to another [18]. Thus in this case, the risk of rectal toxicity 
is increased and it is of importance to make a daily imaging control. The robustness investigation 
of dose distributions showed that the impact of 2 mm isocentre shifts provided very low and 
similar dose deviations for Monaco and Pinnacle plans : Table 3 showed that the dose deviations 
were always less than 5% of the prescribed dose and the dose deviations differences were less 
than 1% of the prescribed dose between the both TPS. Therefore both TPS provided robust plans. 
 
To conclude on this part, most of the differences observed may be closely linked to the objective 
functions used for optimizing the dose distribution. Whereas on both TPS biological and physical 
cost functions are available, Monaco planner chose to use biological in combination with physical 
cost functions while Pinnacle planner used only physical cost functions. In one study IMRT plans 
performed with Pinnacle and Monaco biological-dose based prescriptions were compared to 
Pinnacle physical-dose based prescriptions [19]. Biological prescription led to improve OARs 
sparing compared to physical dose based prescription with a similar performance for Monaco and 
Pinnacle. Contrarily to Qi et al, another study comparing VMAT plans performed with Pinnacle 
biological, physical and mixed prescriptions reported that, in some particular cases, the physical 
prescriptions result in superior treatment plans [20]. Therefore, there is still an open debate on the 
question of the superiority of the biological against physical cost functions.  
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In practice, it is possible to get the same results using physical or biological cost functions even 
though physical cost functions are not as easy to control since one constraint only controls one 
dose point. Therefore one single biological cost function will always lead to a better dosimetric 
solution than one single physical cost function, but is this true for one biological cost function 
against 3 physical cost functions? There will always be a high proportion of subjectivity 
concerning all the studies performed on this subject since the results highly depend: 
1/ on the planner and his degree of experience with either physical or biological cost functions 
2/ on how many physical and biological cost functions are used in the prescription 
The above papers did not give any details about the prescription templates the authors used to get 
their results. In the present study, the planners had to use the prescription template that they had 
found to be best suitable for treating prostate cancer. Monaco planner chose to combine 
biological and physical cost functions, since from their practices, the best results were obtained 
with mixed prescriptions, whereas Pinnacle planner preferred physical cost functions, since they 
did not get better results with biological prescriptions.  
 
Regarding the treatment delivery efficiency, the treatment control system of the Elekta 
accelerator adjusts the dose rate, the gantry and leaves speeds to offer the lowest delivery time 
possible for VMAT plans. This adjustment is efficient since despite different numbers of MUs, 
Monaco and Pinnacle plans were delivered with similar times. We noticed this adjustment 
particularly with the dose rate variation; Monaco plans were delivered with time–average dose 
rate 44% higher than Pinnacle plans. Previous studies compared VMAT performed with Monaco 
or other TPS [3;4]. Similarly to our results they found that Monaco provided more MUs than 
other TPS.  
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Concerning QA analysis, many precautions have been taken. First, to limit the impact of the 
beam-modeling, one set of beam data was used for the commissioning of both TPS [15;21]. 
Previous QA results showed that TPS commissioning are consistent for Monaco and Pinnacle. 
We found similar dosimetric agreement for static fields for both TPS: for 3×3 cm² and 20×20 cm² 
field sizes the mean gamma values were 0.208 and 0.238, and 0.163 and 0.265 in a homogeneous 
phantom for Monaco and Pinnacle, respectively.  
Then to avoid uncertainties with QA implementation, the same operator performed the 
measurements simultaneously for both TPS on the linear accelerator. Our results demonstrated a 
high passing rate for VMAT plan QA for both TPS. Nevertheless, Monaco provided better 
dosimetric agreement than Pinnacle. However, the lowest dosimetric agreement results were 
obtained for the planes where the highest dose-gradients were observed (i.e. sagittal Pinnacle 
planes).  
In addition to this data , film analysis in an anthropomorphic phantom showed that for both TPS 
more than 98 % of points passed the (3%, 3 mm) gamma index criterion. Therefore, the dose 
algorithm accuracy of both TPS was verified in inhomogeneous conditions for pelvis cases thus 
proving that that there is no advantage to use Monaco at the expense of Pinnacle regarding to 
dosimetric accuracy for the studied case.  
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CONCLUSION 
For prostate cancer patients, VMAT planned with Monaco and Pinnacle TPS offered clinically 
acceptable dose distributions. Monaco plans showed enhanced OAR sparing but lower doses into 
the PTV compared to Pinnacle plans. Similar delivery times were found for both TPS but 
Pinnacle solution required less MUs. Finally, a good dosimetric agreement with measured doses 
was achieved with both TPS, but Monaco offered a slightly higher passing rate in the gamma 
index analysis. Further investigations are in progress to confirm the performances of both TPS on 
more complex volumes (head and neck cancer or prostate with pelvic node involvement).  
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Figures and Tables legends: 
Figure 1. Patient-averaged dose distribution differences for axial (A), coronal (B) and sagittal (C) 
views. Data are presented as Pinnacle dose distribution minus Monaco dose distribution: Areas 
where Pinnacle delivered more dose than Monaco are in red color. Areas where Monaco 
delivered more dose are in purple color.  
Figure 2. Average composite DVHs for VMAT performed either with Monaco (continuous grey 
lines) or Pinnacle (continuous black lines) for the rectal wall (A), the bladder wall (B), the 
femoral heads (C), PTV2 (C), healthy tissue (D) and PTV1 (D). The dashed curves (in grey or 
black, for Monaco and Pinnacle TPS respectively) delineate the 95% confidence interval for each 
TPS.  
 
Figure 3. Area and dose rate variation as a function of gantry angle during VMAT delivery for a 
representative patient 
 
Table 1. Objective functions and parameters used in Monaco and Pinnacle. Phase 1 and phase 2 
dose values are mentioned as starting value for the optimization stage.   
Abbreviations: X-Y mm PTV Ring = Volume from X to Y mm of PTV, 30 mm PTV Ring = 
Volume from 30 mm of PTV to external contour. *This function is turned on only after the 
segmentation stage to optimize the PTV coverage. These functions have the “optimized over all 
voxels in volume” option activated (i.e: gives priority to this constraint compared to others). 
 
Table 2. Average dosimetric indices of bladder wall, rectum wall, femoral heads, healthy tissue, 
PTV1 and PTV2 from VMAT with Monaco or Pinnacle. P<0.05 was considered significant for 
Wilcoxon test. 
 20 
Abbreviations: PTV = planning target volume; D mean (Gy) = mean dose to the volume; D max (Gy) = 
max dose to the volume; Vx% = percentage structure volume of x% prescription dose; Dx% = Dose 
received by x% percent of structure volume; HI = homogeneity index; CI = conformity index; 
HCO = healthy tissue coverage index. Data in parentheses are standard deviations. 
 
Table 3. Dosimetric indices of PTV2, bladder wall and rectum wall with and without 2 mm 
isocenter shift in anterior and posterior directions for Monaco and Pinnacle. 
Abbreviations: PTV = planning target volume; D mean (Gy) = mean dose to the volume; D max (Gy) = 
max dose to the volume; Vx% = percentage structure volume of x% prescription dose; Dx% = Dose 
received by x% percent of structure volume 
 
 
Table 4. Patient-average QA results and efficiency. 
Data presented as mean [minimal - maximal] values.  
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Table 1 
 
  Monaco    Pinnacle  
 
Biological / 
Physical 
cost functions 
Cost function  
parameters Phase 1 – 2  
DVH  
constraints Phase 1- 2 
Relative 
weighting 
PTV Target EUD Poisson statistic cell kill 
model 4500 – 3150 cGy PTV Dmin  4760 – 3160 cGy 100 
 
 Cell sensitivity = 0.5  
 
Uniform Dose 4780 – 3200 cGy 100 
 
Quadratic overdose  4620 – 3220 cGy 
 
Dmax  4800 – 3240 cGy 100 
 
 RMS Excess  40 
 
   
 
Underdose DVH* 90-95 %  V 4395 – 3065 cGy 
 
   
Rectum Serial Cost function Power law exponential = 13 4000 – 2800 cGy Rectal wall 30%  V 1785 – 1230 cGy 2 
 
Maximum Dose  4680 – 3250 cGy 
 
15%  V 2760 – 1930 cGy 2 
 
Serial Cost function Power law exponential = 5 2800 – 1950 cGy 
 
5%  V 3795 – 2640 cGy 2 
 
 Shrink Margin = 0.40 cm  
 
Dmax  4200 – 2830 cGy 80 
 
Parallel Cost Function Power law exponential = 3.5 2600 – 1800 cGy 
 
   
 
 Mean organ Damage 45 % 
 
   
Bladder Serial Cost function Power law exponential = 9 4000 – 2800 cGy Bladder  wall Dmax  4300 – 2955 cGy 100 
 
Maximum Dose  4720 – 3280 cGy 
 
   
 
Serial Cost function Power law exponential = 5 2800 – 1950 cGy 
 
   
 
 Shrink Margin = 0.40 cm  
 
   
 
Parallel Cost Function Power law exponential = 3 2700 – 1900 cGy 
 
   
 
 Mean organ Damage 45 % 
 
   
Femoral Heads  None  Femoral Heads Dmax  2000 – 1435 cGy 1 
Healthy Quadratic overdose Shrink margin = 0.5 cm 3300 – 2300 cGy 2 – 7 mm PTV ring Dmax  4370 – 3040 cGy 50 
tissue  RMS Excess   40 7– 12 mm PTV ring Dmax  4140 – 2880 cGy 50 
 
Quadratic overdose Shrink margin = 1 cm 2650 – 1850 cGy 30 mm PTV ring Dmax  2300 – 1600 cGy 10 
 
 RMS Excess  40 
 
   
 
Maximum Dose Shrink Margin = 0 4920 – 3420 cGy 
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Table 2  
 
 Monaco Pinnacle Wilcoxon test  Monaco Pinnacle Wilcoxon test 
Rectal wall    PTV1    
Dmax (Gy) 75.1 (0.5) 74.7 (0.8) 0.385 Dmean (Gy) 73.2 (2.8) 74.9 (3) 0.008 
Dmean (Gy) 46.1 (5.7) 43.4 (7.2) 0.047     
D25% (Gy) 61.7 (7.6) 60.5 (8.5) 0.093     
D50% (Gy) 45.4 (8.4) 41.5 (9.9) 0.047     
Bladder wall    PTV2    
Dmax (Gy) 77.9 (0.7) 78.1 (1.1) 0.541 Dmean (Gy) 78.4 (0.4) 78.9 (0.8) 0.241 
Dmean (Gy) 31.9 (7.3) 33.9 (8.3) 0.019 Dmax (Gy) 81.7 (0.7) 81.1 (1.1) 0.102 
D25% (Gy) 52.1 (12.6) 54.5 (11.5) 0.221 D5% (Gy) 81.1 (0.6) 80.8 (1) 0.260 
D50% (Gy) 22.4 (9.4) 24.7 (10.9) 0.202 D95% (Gy) 74.7 (0.2) 75.4 (0.6) 0.005 
Femoral heads        
Dmean (Gy) 19.6 (3.5) 25.3 (2.7) 0.017     
D5% (Gy) 33.1 (5.3) 37.1 (2.5) 0.059     
Patient    Quality indexes    
Dmean (Gy) 8.3 (1.2) 9.2 (1.4) 0.005 HI 0.08 (0.01) 0.07 (0.01) 0.027 
Dmax (Gy) 82.1 (0.7) 81.2 (1.1) 0.047 CI 1.19 (0.08) 1.30 (0.08) 0.036 
V5% (cc)  34.8 (4.3) 36.4 (4.7) 0.008 HCO 18.10 (4.40) 25.37 (6.04) 0.028 
V10% (cc) 29.4 (3.7) 30.5 (4.1) 0.053     
V95% (cc) 1.1 (0.3) 1.2 (0.4) 0.012     
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Table 3 
 
 Without shift 
2 mm shift 
in anterior direction 
2 mm shift 
in posterior direction 
 Monaco Pinnacle Monaco Pinnacle Monaco Pinnacle 
PTV2       
Dmean (Gy) 78.8 78.5 78.6 78.3 78.8 78.7 
Dmax (Gy) 83.0 81.1 82.8 81.0 82.9 81.2 
D5% (Gy) 81.9 80.6 81.8 80.6 81.9 80.8 
D95% (Gy) 74.8 74.9 74.1 73.6 74.8 75.2 
Rectum wall       
Dmax (Gy) 74.0 74.4 72.7 73.2 75.3 75.7 
Dmean (Gy) 46.4 47.4 44.7 45.8 48.3 49.1 
D25% (Gy) 65.3 65.3 61.9 61.5 68.3 68.5 
D50% (Gy) 46.9 47.9 45.3 46.7 48.8 49.3 
Bladder wall       
Dmax (Gy) 77.2 77.8 77.5 78.0 76.9 77.6 
Dmean (Gy) 27.6 26.8 28.4 27.5 27.2 26.2 
D25% (Gy) 44.8 41.8 46.1 43.1 43.5 40.6 
D50% (Gy) 20.7 19.2 21.5 19.6 20.3 18.7 
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Table 4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Monaco Pinnacle 
 Coronal Sagittal Coronal Sagittal 
γ index test: criterion 3% / 3mm, dose level: 30% 
% accepted point 100 98.5 98.2 97.4 
γ mean 0.24 0.31 0.38 0.40 
γ max 0.78 1.22 1.37 1.33 
Dose gradient 
Mean gradient (cGy/mm) 4.6 4.6 4.3 5.1 
Maximum gradient (cGy/mm) 25.6 28.3 29.4 32.8 
Efficiency 
Delivery time (s) 169 [130-237]  165 [139-203]  
MU 688 [477-902]  452 [322-614] 
Mean Dose Rate (MU/min) 230 160 
Mean Area (cm²) 2.6 [2.0-3.9] 4.1 [2.6-6.7] 
Minimum Area (cm²) 0.5 [0.2-1.0] 1.3 [0.7-3.0] 
Maximum Area (cm²) 4.9 [3.4-7.7] 6.3 [4.1-8.6] 
